KouTech completes Series B financing raising hundreds of millions to accelerate high-precision surgical robot platform
KouTech Medical Technology (Shanghai) Co., Ltd. ("KouTech"), a company deeply dedicated to supramicrosurgery and high-precision surgical robots, recently announced the completion of a Series B financing round that raised several hundred million yuan. This round saw participation from both industrial capital and renowned investment institutions. The proceeds will be primarily used to consolidate the technological advantages of its core products, complete the ecosystem of its microsurgery robot product series, accelerate the clinical registration process, and advance its global market expansion strategy.
Founded in 2022, KouTech is the world's first innovative company focused on a platform for compact, high-precision surgical robots. Its predecessor provided R&D and production services for high-precision intelligent devices to several internationally renowned medical device companies, accumulating over a decade of profound technical expertise in the field of precision medical device manufacturing.
By leveraging its joint R&D centers in the United States and Japan, KouTech has independently developed underlying components, servo systems, transmission mechanisms, and consumable components for its surgical robots, breaking through the bottleneck of Chinese companies' reliance on imported key technologies. Furthermore, the company has established in-depth collaborations with numerous global universities and research institutions to jointly advance the development of engineering components and systems, forming a complete innovation chain from foundational technology to clinical application.
KouTech focuses on the development of high-precision platform-based surgical robots. Its product portfolio covers a general-purpose microsurgery robot, an ophthalmic surgery robot, and related innovative consumables for multi-departmental robotic applications. The core technological breakthrough lies in achieving sub-micron-level single-step motion precision and entirely tremor-free operation, equipped with a 7-degree-of-freedom wrist-joint design tailored for complex maneuvers within confined surgical spaces.
These product innovations are at the forefront of global surgical robot technology and have gained widespread recognition from clinicians at numerous top-tier hospitals in China. KouTech has established collaborations with leading medical institutions such as Shanghai Ninth People's Hospital, Shanghai jiaoTong University School of Medicin, Ningbo No.6 Hospital, and Peking University School and Hospital of Stomatology to jointly promote the clinical deployment and continuous optimization of its surgical robots.
At the 5th Annual Conference of Microsurgeons of the Chinese Medical Doctor Association, Professor Zhang Yixin and Associate Chief Physician Feng Shaoqing from the Department of Plastic and Reconstructive Surgery at Shanghai Ninth People's Hospital delivered academic presentations. The microsurgery system demonstrated during their reports was the Kai microsurgery robot platform, independently developed by KouTech.
Human eye tissue is exceptionally fragile, and the surgical operating space is extremely limited. Traditional ophthalmic surgery is constrained by challenges such as the surgeon's physiological hand tremor (an inherent human tremor of approximately 100 microns), the limits of visual field magnification, and fatigue-related errors, making it difficult to achieve breakthroughs in stability and precision. The ophthalmic surgical robot independently developed by KouTech is a high-precision solution specifically designed to address these clinical challenges.
KouTech's independently developed ophthalmic surgical robot integrates high-precision control algorithms with flexible micro-mechanisms. It achieves sub-micron level single-step motion, effectively filters out physiological hand tremor, assists surgeons in surpassing physiological limits, meets the operational demands of high-precision intraocular surgery, shortens the learning curve for surgeons, transcends individual skill ceilings, and improves surgical success rates.
It is reported that KouTech's ophthalmic surgical robot has recently completed its registration clinical trial in China, formally entering the critical stage of market registration and approval.
In addition to ophthalmology, KouTech has also achieved rapid breakthroughs in the field of microsurgery robots. According to public reports, the company's microsurgery robot, Kai, has been applied across various disciplines including plastic and reconstructive surgery, maxillofacial surgery, hand surgery, and reconstructive surgery, demonstrating strong platform extensibility and versatility.
This microsurgery robot features multiple degrees of freedom within a compact form factor, allowing for rapid deployment in the operating room. Its front end can be equipped with instruments such as the world's smallest forceps, with a diameter of only 2 millimeters and seven degrees of freedom at the tip, enabling high-precision anastomosis of blood and lymphatic vessels as small as 0.3 mm in diameter while maintaining sub-millimeter consistency throughout prolonged procedures. The system provides high-definition 3D stereoscopic vision, capable of identifying fine anatomical structures and tension changes. Its lightweight and compact design facilitates easy positioning, allowing flexible access to deep head and neck areas, small joint spaces, and other confined surgical fields, while also supporting integrated multi-departmental deployment and teaching applications.
KouTech's microsurgery robot has already been validated in several clinical procedures:
In June 2025, it assisted the Microsurgery Center at Shanghai Ninth People's Hospital in performing the world's first robot-assisted resection of a giant dermatofibrosarcoma protuberans.
In July 2025, it was successfully used at Ningbo No.6 Hospital for Zhejiang Province's first domestically developed microsurgery robot-assisted superthin perforator flap transplantation.
In July 2025, it successfully completed a delicate anastomosis of the superficial temporal artery and retroauricular vein at Shanghai Ninth People's Hospital, applied for complex scalp scar repair.
In September 2025, it supported Peking University School and Hospital of Stomatology in completing China's first microsurgery robot-assisted vascularized free flap reconstruction for maxillofacial defects.
These cases demonstrate the robot's promising feasibility and stability across various clinical scenarios. It not only functions as a specialized device but also holds significant potential to evolve into a versatile surgical platform capable of supporting multi-disciplinary procedures, thereby promoting the wider adoption of complex surgical techniques. Currently, the device remains in the clinical validation stage. The company plans to further expand its range of indications and continuously optimize the system's performance through collaborations with leading medical institutions.